Study assesses efficacy of CSII in type 1 diabetes

Continuous subcutaneous insulin infusion (CSII) improves glycaemic control in patients with type 1 diabetes, UK researchers show.

Their 12-year study of 327 patients shows a 0.7% drop in HbA1c that persisted for seven years.  

Patients with poor glycaemic control achieved a 1.1% drop in HbA1c sustained over six years, although they did not achieve the target HbA1c concentration of 53mmol